What Lysando does

Lysando AG is a privately held biotech company headquartered in Triesenberg, Liechtenstein, that develops and commercializes Artilysin® technology — a class of precision-designed antimicrobial molecules that target and eliminate harmful bacteria while preserving beneficial microbiome communities. The company's core technology addresses the global antibiotic resistance crisis through a mechanism that avoids triggering resistance, rebalances biofilms rather than destroying them, and is effective against metabolically inactive persistent bacteria. Lysando applies AI-driven protein design, supported by a proprietary database of over 4,500 constructs and modules, to accelerate the development of new Artilysin® variants. The intellectual property portfolio comprises hundreds of national patents protecting the Artilysin® platform.

The company's product portfolio spans multiple therapeutic areas: wound care solutions for chronic wounds and infections, dermatology products for acne and eczema, Medolysin® as a specialized variant for medical and veterinary applications (including mastitis in dairy cows through the Amicogen partnership), and general microbiome health applications covering pyoderma, UTIs, and related conditions. The primary go-to-market motion is enterprise field sales and direct B2B engagement with pharmaceutical companies, healthcare providers, and research institutions, utilizing contact forms and downloadable brochures rather than standard product distribution channels. Revenue derives from product sales and technology licensing/royalties, though pricing is not publicly disclosed.

Lysando has established strategic partnerships with Amicogen Inc. (a South Korean enzyme specialist with mutual cross-ownership since 2021) and AiCuris Anti-Infective Curies GmbH (collaborating on diabetic foot infections), indicating a co-development and licensing-driven business model. The company has built out its leadership team with specialized hires including a CSO (Yong Chul Shin, Ph.D.), CFO, and Director of Strategy & Business Development, supplemented by four advisory board appointments in 2024. In July 2024, Lysando entered the Ukrainian market through a humanitarian collaboration with Bamberg UA, donating Medolysin® to address antibiotic resistance in Ukrainian hospitals.

Name

Lysando

Legal name

LYSANDO AG

Website

https://www.lysando.com

Company type

Private

Operating status

Operating

Short description

Lysando AG is a Liechtenstein-based biotech company developing Artilysin® molecules — precision-designed antimicrobial proteins that target harmful bacteria while preserving microbiome balance. It serves pharmaceutical partners and healthcare providers across wound care, dermatology, and animal health applications.

Ownership category

akta.pro rank

Product category

Antimicrobial Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Antimicrobials & Anti-infectives (HLAMAEAE)

akta.pro secondary industries

Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC), Dermatology & Allergy Drugs (HLAMAEAH), Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

Keywords

• Antimicrobial protein therapeutics
• Microbiome-friendly treatments
• Antibiotic resistance solutions
• AI-driven protein design
• Precision antimicrobials

Headquarters

HQ city

Triesenberg

HQ country

Liechtenstein

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Product Sales / Licensing: Lysando develops and commercializes Artilysin-based products for healthcare applications including wound care, dermatology (acne, eczema), and microbiome health. Revenue likely derives from product sales and technology licensing to pharmaceutical and healthcare companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Lysando develops and commercializes Artilysin® technology, a class of precision-designed antimicrobial protein molecules that selectively eliminate harmful bacteria while preserving beneficial microbiome communities. The company applies AI-driven protein design, supported by a proprietary database of more than 4,500 constructs, to develop therapeutic products for wound care, dermatology (acne, eczema), and animal health applications such as mastitis in dairy cattle. Revenue derives from product sales of Artilysin-based therapeutics and licensing of the underlying technology to pharmaceutical and healthcare partners.

Product overview

Lysando AG is a biotech company that has developed Artilysin® technology as its core platform - a groundbreaking class of precision-designed molecules for microbiome-targeted treatments. The company offers products targeting wound care and dermatology (acne, eczema), with Medolysin® serving as a specialized variant for medical and veterinary applications. Lysando employs AI-driven protein design with a proprietary database of over 4,500 constructs to enable rapid development of new therapeutic candidates. The portfolio centers on microbiome modulation rather than indiscriminate bacterial elimination, positioning Artilysin® as an alternative to conventional antibiotics.

Differentiator

Problem solved

Functional benefit

Brands

• Artilysin®: A groundbreaking new class of precision-designed molecules that reestablish microbiome harmony and address the root cause of bacterial infections. Artilysins are developed using AI-driven protein design and target harmful bacteria while preserving beneficial microbiome populations.
• Medolysin®

Products and services

• Artilysin®

Quantifiable outcome

• No resistance to Artilysins observed despite rigorous testing

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Bamberg UA (Ukrainian Association)minorGTM or Marketing Partner · 1 July 2024Innovation meets compassion collaboration where Lysando and Bamberg UA are working together to tackle antibiotic resistance in Ukrainian hospitals with Medolysin donation.
• Amicogen Inc.coreStrategic or Co-development Partner · 8 May 2023Novel approach for the treatment of mastitis in dairy cows, providing an antibiotic-free alternative for livestock health management.
• Amicogen Inc.coreStrategic or Co-development Partner · 18 October 2022Strategic partnership including general development agreement for novel approaches in microbiome modulation. The partnership includes mutual ownership participations in each other's companies, indicating deep strategic alignment. Collaboration includes treatment of mastitis in dairy cows and potential broader applications in animal and human health.
• AiCuris Anti-Infective Curies GmbHcoreStrategic or Co-development PartnerAiCuris announced expansion of collaboration with Lysando focusing on diabetic foot infections, leveraging Artilysin technology for difficult-to-treat bacterial infections.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• AiCuris Anti-Infective Cures: AiCuris is a specialty anti-infective company with a broader anti-infective pipeline. As Lysando's announced collaboration partner for diabetic foot infections, it operates in the same anti-infective space but with a wider portfolio beyond microbiome-targeted approaches.
• Iterum Therapeutics: Iterum Therapeutics develops antibiotics targeting multi-drug resistant infections. While it operates in the same anti-infective space with conventional small-molecule antibiotics, it represents the established incumbent approach that Artilysins aim to displace.

Direct peers

• Locus Biosciences: Locus Biosciences develops engineered bacteriophage-based antimicrobials targeting antibiotic-resistant bacteria. Its precision antimicrobial approach for treating resistant infections makes it a direct peer to Lysando's Artilysin technology.
• Phagelux: Phagelux develops phage-based products for bacterial infection control across human health, animal health, and food safety. Its multi-species antimicrobial platform and animal health focus directly parallel Lysando's positioning with Amicogen.
• ContraFect: ContraFect develops lysin-based therapeutics targeting serious bacterial infections, including drug-resistant pathogens. Its lysin modality is mechanistically similar to Artilysins, making it a direct peer in the novel antimicrobial protein space.
• Kane Biotech: Kane Biotech develops biofilm-disrupting antimicrobial wound care products. Its focus on biofilm management in wound applications directly overlaps with Lysando's wound care use case, even though the underlying modality differs.
• Eligo Bioscience: Eligo Bioscience develops precision antimicrobials using engineered phage-derived payloads to selectively eliminate specific bacteria. Its microbiome-preserving approach for targeted bacterial elimination directly parallels Lysando's Artilysin strategy.
• Micreos: Micreos develops endolysin-based antimicrobial products (e.g., Staphefekt) that selectively target pathogenic bacteria while preserving beneficial microbiome. Its technology is the closest analog to Lysando's Artilysin platform, making it a direct peer in the precision antimicrobial space.

Emerging players

• MatriSys Bioscience: MatriSys Bioscience develops live biotherapeutic products targeting skin microbiome for dermatological conditions. Its microbiome-focused approach to skin diseases provides a partial overlap with Lysando's dermatology indications.
• Siolta Therapeutics: Siolta Therapeutics develops microbiome-based therapeutics for inflammatory diseases including atopic dermatitis. Its focus on microbiome modulation for skin conditions overlaps with Lysando's dermatology use cases (acne, eczema).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lysando